Evidence map›Paper›PMID 12185585›Full record

ArticleOncogene2002

Identification of membrane-type matrix metalloproteinase-1 as a target of the beta-catenin/Tcf4 complex in human colorectal cancers.

Meiko Takahashi, Tatsuhiko Tsunoda, Motoharu Seiki, Yusuke Nakamura, Yoichi Furukawa

2 registry-linked trialsAbstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 84 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed, 1 pooled it
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00681252 phase1 / phase2completednot on this mapstarted 2008, after this paper: background citation

Phase I/II Study of Multiple-Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*0201 in Treating Patients With Refractory Gastric Cancer

TypeinterventionalSponsorTokyo UniversityRan2008 to 2009Enrolled14ConditionsGastric CancerArmsURLC10, VEGFR1 and VEGFR2
NCT00681421 phase1 / phase2completednot on this mapstarted 2008, after this paper: background citation

Phase I/II Study of Multiple-Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*0201 in Treating Patients With Refractory Esophageal Cancer

TypeinterventionalSponsorTokyo UniversityRan2008 to 2009Enrolled14ConditionsEsophageal CancerArmsURLC10, VEGFR1 and VEGFR2
3 · Its place in the literature

Who cites it

84 citing papers in PubMed, 1 synthesis or guideline pooled it, 232 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. The Role of EMT-Related lncRNAs in Ovarian Cancer.International journal of molecular sciences · 2023
    Review
  4. Article
  5. Article
  6. Root Bark ofJournal of microbiology and biotechnology · 2021
    Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Tumour budding in colorectal cancer: what do we know and what can we do?Virchows Archiv : an international journal of pathology · 2016
    Review

24 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Meiko TakahashiLaboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Minato-ku, Japan.
Tatsuhiko Tsunoda
Motoharu Seiki
Yusuke Nakamura
Yoichi Furukawa
The University of Tokyo · JPRIKEN · JPTokyo University of Science · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Genetic alterations of APC and CTNNB1 (beta-catenin) have been identified in a number of human cancers including tumors arising in the colon and liver. Mutations in these genes lead to abnormal accumulation of beta-catenin and constitutive activation of target genes in the Wnt signaling pathway. To clarify the precise role of accumulated beta-catenin in colorectal carcinogenesis, we searched for genes involved in the beta-catenin/Tcf signaling pathway by cDNA microarray. MT1-MMP (membrane-type matrix metalloproteinase) was among 84 genes that were down-regulated after beta-catenin had been depleted by transduction of wild-type APC in SW480 cells. Expression of MT1-MMP was elevated in 22 of 24 colon carcinomas we examined. Reporter assays and an electromobility-shift assay revealed a DNA fragment between -1169 bp and -1163 bp in the 5' flanking region of this gene to be a target of the beta-catenin/Tcf4 complex. Our results indicate that MT1-MMP is a direct down-stream target in the Wnt signaling pathway, and that one of the ways accumulated beta-catenin contributes to colorectal carcinogenesis is by transactivating this gene.

Indexed as

5' Flanking Regionbeta CateninBinding SitesColorectal NeoplasmsCytoskeletal ProteinsHumansMatrix Metalloproteinases, Membrane-AssociatedMetalloendopeptidasesPromoter Regions, GeneticTCF Transcription FactorsTrans-ActivatorsTranscription Factor 7-Like 2 ProteinTranscription FactorsTumor Cells, Culturedbeta CateninCTNNB1 protein, humanCytoskeletal ProteinsMatrix Metalloproteinases, Membrane-AssociatedMetalloendopeptidasesTCF7L2 protein, humanTCF Transcription FactorsTrans-ActivatorsTranscription Factor 7-Like 2 ProteinTranscription Factors

Identifiers

PMID12185585
OpenAlexW2069561137

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.